All In Biotech

Drug Trial Radar · NCT00251693

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis

Last checked: Nov 20, 2026Latest source record: Feb 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,038 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,038

Actual

Start

Dec 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.

Conditions

  • Esophagitis, Reflux
  • Esophagitis, Peptic

Interventions

  • Dexlansoprazole MRDrug

    Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.

  • Dexlansoprazole MRDrug

    Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.

  • LansoprazoleDrug

    Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.Time frame: 8 Weeks
  2. Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.Time frame: 8 weeks

Locations

140 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Alabaster, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Chula Vista, California

  • Site not named

    Fullerton, California

  • Site not named

    Garden Grove, California

  • Site not named

    Irvine, California

  • Site not named

    Lancaster, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Hills, California

  • Site not named

    Palm Springs, California

  • Site not named

    Pasadena, California

  • Site not named

    Redwood City, California

  • Site not named

    San Diego, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    Boulder, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Lone Tree, Colorado

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Jacksonsville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Lakeland, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Hines, Illinois

  • Site not named

    Oak Park, Illinois

  • Site not named

    Rockford, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Dubuque, Iowa

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.